By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Shire LLC et al. v. Mylan Pharmaceuticals Inc. et al.
1:11-cv-00201; filed December 15, 2011 in the Northern District of West Virginia
• Plaintiffs: Shire LLC; Supernus Pharmaceuticals, Inc.; Shire Development Inc.; Shire International Licensing B. V.; Amy F. T. Arnsten, Ph.D.; Robert D. Hunt, M.D.; Pasko Rakic, M.D.
• Defendants: Mylan Pharmaceuticals Inc.; Mylan, Inc.
Infringement of U.S. Patent Nos. 5,854,290 ("Use of Guanfacine in the Treatment of Behavioral Disorders," issued December 19, 1998), 6,287,599 ("Sustained Release Pharmaceutical Dosage Forms with Minimized pH Dependent Dissolution Profiles," issued September 11, 2001), and 6,811,794 (same title, issued November 2, 2004) based on Mylan's filing of an ANDA to manufacture a generic version of Shire's Intuniv® (guanfacine, used to treat attention-deficit hyperactivity disorder). View the complaint here.
Cephalon, Inc. et al. v. Celgene Corp. et al.
1:11-cv-12226; filed December 14, 2011 in the District Court of Massachusetts
• Plaintiffs: Cephalon, Inc.; Acusphere, Inc.
• Defendants: Celgene Corp.; Abraxis Bioscience, Inc.; Abraxis Bioscience, LLC
Infringement of U.S. Patent No. RE40,493 (""Porous Paclitaxel Matrices and Methods of Manufacture Thereof," reissued September 9, 2008) based on Celgene's manufacture and sale of its Abraxane® product (paclitaxel protein-bound particles for injectable suspension; used for the treatment of breast cancer). View the complaint here.
Janssen Pharmaceuticals, Inc. et al. v. Sandoz, Inc.
3:11-cv-07247; filed December 13, 2011 in the District Court of New Jersey
• Plaintiffs: Janssen Pharmaceuticals, Inc.; Peninsula Pharmaceuticals, Inc.; Shionogi & Co. Ltd.
• Defendant: Sandoz, Inc.
Infringement of U.S. Patent No. 5,317,016 ("Pyrrolidylthiocarbapenem Derivative," issued May 31, 1994) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Janssen's Doribax® (doripenem injecction, used to treat complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis). View the complaint here.
Warner Chilcott Co., LLC v. Lupin Ltd. et al.
3:11-cv-07228; filed December 12, 2011 in the District Court of New Jersey
• Plaintiff: Warner Chilcott Co., LLC
• Defendants: Lupin Ltd.; Lupin Pharmaceuticals, Inc.
Infringement of U.S. Patent No. 6,667,050 ("Chewable Oral Contraceptive, " issued December 23, 2003) following a Paragraph IV certification as part of Lupin's filing of an ANDA to manufacture a generic version of Warner Chilcott's GeneressTM Fe (norethindrone and ethinyl estradiol, used for oral contraception). View the complaint here.
Alza Corp. v. Mylan Pharmaceuticals Inc. et al.
2:11-cv-07158; filed December 9, 2011 in the District Court of New Jersey
• Plaintiff: Alza Corp.
• Defendants: Mylan Pharmaceuticals Inc.; Mylan Inc.
Infringement of U.S. Patent No. 5,591,454 ("Method For Lowering Blood Glucose," issued January 7, 1997), licensed to Pfizer, following a Paragraph IV certification as part of Mylan's filing of an amendment to its ANDA (adding additional dosage forms) to manufacture a generic version of Pfizer's Glucotrol XL® (glipizide extended release tablets, used to improve glycemic control in adults with type 2 diabetes mellitus). View the complaint here.
PAMLAB, L.L.C. et al. v. Macoven Pharmaceuticals, L.L.C.
1:11-cv-09022; filed December 9, 2011 in the Southern District of New York
• Plaintiffs: PAMLAB, L.L.C.; Metabolite Laboratories, Inc.; Breckenridge Pharmaceutical, Inc.
• Defendant: Macoven Pharmaceuticals, L.L.C.
Infringement of U.S. Patent No. 6,528,496 ("Compositions Treating, Preventing, or Reducing Elevated Metabolic Levels," issued March 4, 2003) based on Macoven's manufacture, sale, and offer for sale of folic acid products allegedly represented to be substitutable for plaintiffs' Foltx® and/or Folbic® products (vitamin B12, vitamin B6, and folic acid, used to treat hyperhomocysteinemia). View the complaint here.
Comments